197 related articles for article (PubMed ID: 29576280)
1. Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
Yang HY; Sun LJ; Mao YL
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):93-94. PubMed ID: 29576280
[No Abstract] [Full Text] [Related]
2. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
3. Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.
Lipson EJ; Lilo MT; Ogurtsova A; Esandrio J; Xu H; Brothers P; Schollenberger M; Sharfman WH; Taube JM
J Immunother Cancer; 2017; 5():23. PubMed ID: 28344809
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.
Onuma AE; Zhang H; Huang H; Williams TM; Noonan A; Tsung A
Gene Expr; 2020 Jun; 20(1):53-65. PubMed ID: 32340652
[TBL] [Abstract][Full Text] [Related]
5. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.
Dodagatta-Marri E; Meyer DS; Reeves MQ; Paniagua R; To MD; Binnewies M; Broz ML; Mori H; Wu D; Adoumie M; Del Rosario R; Li O; Buchmann T; Liang B; Malato J; Arce Vargus F; Sheppard D; Hann BC; Mirza A; Quezada SA; Rosenblum MD; Krummel MF; Balmain A; Akhurst RJ
J Immunother Cancer; 2019 Mar; 7(1):62. PubMed ID: 30832732
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment.
Ren Z; Yang K; Zhu L; Yin D; Zhou Y
Int Immunopharmacol; 2024 May; 132():111934. PubMed ID: 38574701
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?
Moreno-Vicente J; Beers SA; Gray JC
Cancer Lett; 2019 Aug; 457():74-85. PubMed ID: 31055109
[TBL] [Abstract][Full Text] [Related]
8. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.
Liberini V; Laudicella R; Capozza M; Huellner MW; Burger IA; Baldari S; Terreno E; Deandreis D
Molecules; 2021 Apr; 26(8):. PubMed ID: 33920423
[TBL] [Abstract][Full Text] [Related]
9. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.
Agdashian D; ElGindi M; Xie C; Sandhu M; Pratt D; Kleiner DE; Figg WD; Rytlewski JA; Sanders C; Yusko EC; Wood B; Venzon D; Brar G; Duffy AG; Greten TF; Korangy F
Cancer Immunol Immunother; 2019 Apr; 68(4):599-608. PubMed ID: 30688989
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas.
Chen J; Li G; Meng H; Fan Y; Song Y; Wang S; Zhu F; Guo C; Zhang L; Shi Y
Cancer Immunol Immunother; 2012 Jan; 61(1):101-8. PubMed ID: 21853301
[TBL] [Abstract][Full Text] [Related]
11. Predicting effect of anti-PD-1/PD-L1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS.
Liu B; Shi J; Su R; Zheng R; Xing F; Zhang Y; Wang N; Chen H; Feng S
Front Immunol; 2024; 15():1370771. PubMed ID: 38707906
[TBL] [Abstract][Full Text] [Related]
12. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.
Botticelli A; Zizzari I; Mazzuca F; Ascierto PA; Putignani L; Marchetti L; Napoletano C; Nuti M; Marchetti P
Oncotarget; 2017 Jan; 8(5):8890-8899. PubMed ID: 27806346
[TBL] [Abstract][Full Text] [Related]
13. Homologous-magnetic dual-targeted metal-organic framework to improve the Anti-hepatocellular carcinoma efficacy of PD-1 inhibitor.
Guo H; Li X; Mao D; Wang H; Wei L; Qu D; Qin X; Li X; Liu Y; Chen Y
J Nanobiotechnology; 2024 Apr; 22(1):206. PubMed ID: 38658950
[TBL] [Abstract][Full Text] [Related]
14. Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade.
Rauch DA; Conlon KC; Janakiram M; Brammer JE; Harding JC; Ye BH; Zang X; Ren X; Olson S; Cheng X; Miljkovic MD; Sundaramoorthi H; Joseph A; Skidmore ZL; Griffith O; Griffith M; Waldmann TA; Ratner L
Blood; 2019 Oct; 134(17):1406-1414. PubMed ID: 31467059
[TBL] [Abstract][Full Text] [Related]
15. PD-L1-PD-1 interactions limit effector regulatory T cell populations at homeostasis and during infection.
Perry JA; Shallberg L; Clark JT; Gullicksrud JA; DeLong JH; Douglas BB; Hart AP; Lanzar Z; O'Dea K; Konradt C; Park J; Kuchroo JR; Grubaugh D; Zaretsky AG; Brodsky IE; Malefyt RW; Christian DA; Sharpe AH; Hunter CA
Nat Immunol; 2022 May; 23(5):743-756. PubMed ID: 35437326
[TBL] [Abstract][Full Text] [Related]
16. Combination strategies for first-line treatment of patients with unresectable hepatocellular carcinoma: prospect of natural products.
Zhang L; Lu J
Chin J Nat Med; 2024 Jan; 22(1):1-3. PubMed ID: 38278555
[No Abstract] [Full Text] [Related]
17. Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8
Bestion E; Rachid M; Tijeras-Raballand A; Roth G; Decaens T; Ansaldi C; Mezouar S; Raymond E; Halfon P
Target Oncol; 2024 Jan; 19(1):95-106. PubMed ID: 38133710
[TBL] [Abstract][Full Text] [Related]
18. Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade.
Daniel SK; Sullivan KM; Dickerson LK; van den Bijgaart RJE; Utria AF; Labadie KP; Kenerson HL; Jiang X; Smythe KS; Campbell JS; Pierce RH; Kim TS; Riehle KJ; Yeung RS; Carter JA; Barry KC; Pillarisetty VG
Sci Rep; 2024 Mar; 14(1):5109. PubMed ID: 38429349
[TBL] [Abstract][Full Text] [Related]
19. Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma.
Kim JW; Lee IJ
Clin Mol Hepatol; 2021 Jan; 27(1):103-106. PubMed ID: 33317257
[No Abstract] [Full Text] [Related]
20. Advancing with cancer immunotherapeutics: CD29
Cubero FJ; Sarobe P; Tiegs G
Gut; 2024 Feb; 73(3):391-392. PubMed ID: 37898547
[No Abstract] [Full Text] [Related]
[Next] [New Search]
